You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Innovative Polishing Technology for Fabrication of High Performance Epi-ready GaSb Substrates

    SBC: Sinmat Inc            Topic: MDA12T003

    Antimony containing III-V semiconducting compounds are particularly attractive for the fabrication of a wide variety of electronic and optoelectronic devices such as photo detectors operating in the long wave infrared wavelength (12-32µm) range. The production of epi quality GaSb wafers still remains one of the important problems for rapid commercialization of GaSb devices. Sinmat Inc. proposes a ...

    STTR Phase I 2013 Department of DefenseMissile Defense Agency
  2. RF-IR Data Fusion

    SBC: DECIBEL RESEARCH, INC.            Topic: MDA12T002

    The development and integration of three unique and innovative algorithm prototypes into a"Fused Track and Characterization Schema"are proposed. This Schema will encompass the determination of signatures and characteristics of objects that can be identified by RF and EO/IR Sensors in order to enable multi-sensor data fusion and correlation. The first algorithm, the"3D Pose Estimation"Algorithm, p ...

    STTR Phase I 2013 Department of DefenseMissile Defense Agency
  3. Post Intercept Debris Predictions for EO/IR Scene Modeling

    SBC: CORVID TECHNOLOGIES, LLC            Topic: MDA12T005

    Corvid Technologies is pleased to offer this STTR Phase I proposal in collaboration with The Johns Hopkins University Applied Physics Laboratory and Spectral Sciences, Incorporated. The emphasis of the proposed effort is to develop a new methodology for predicting late-time EO/IR signatures from high-velocity impacts during a Ballistic Missile Defense intercept event. This collaborative effort w ...

    STTR Phase I 2013 Department of DefenseMissile Defense Agency
  4. Osteochondral tissue repair in an ovine model using a 3D woven poly (e-caprolacto

    SBC: Cytex Therapeutics, Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Standard microfracture is a first-line, widely used and cost-effective surgical technique for repairing damaged articular cartilage, but, it is limited by decreased long-term efficacy and limited applicability in largerlesions. This leads to a burgeoning economic burden associated with primary and follow-up treatment costs, estimated at more than 40 billion dol ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Controlling mechanical signal transduction to treat osteoarthritis

    SBC: Cytex Therapeutics, Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Controlling mechanical signal transduction to treat osteoarthritis Abstract The TRPV4 calcium (Ca++) permeable ion channel has been shown to be expressed and functional in chondrocytes, the cells responsible for the maintenance of cartilage in weight-bearing joints. Trauma of joints with subsequent damage of cartilage, as well as chronically increased joint loa ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Evaluation of a new class of molecules for treating MRSA infective endocarditis

    SBC: AGILE SCIENCES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Patients with infective endocarditis (IE) have a poor prognosis with one third of the patients succumbing to the infection within the first year. Treatments for endocarditis involve antibiotic therapy and/or surgery that cost upwards of 100,000 per patient; however, many cases do not respond to the antibiotic treatment and surgery poses high risks. Cases of en ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Establishing BRM Polymorphisms as Predictive Biomarkers for Lung Cancer Risk

    SBC: ZENAGENE, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): While there is no doubt smoking is a direct causative factor underlying the development of lung cancer, not every smoker develops lung cancer. In fact, only 10-15% of smokers develop this disease, indicating that otherfactors make certain individuals more susceptible to cancer. A number of single nucleotide polymorphisms are known to correlate with the developm ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Targeting c-Myc and Akt with PP2A reactivation therapy for the treatment of breas

    SBC: ONCOTIDE PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Each year in the United States over 270,000 women will be diagnosed with breast cancer and over 40,000 will die from the disease. While multiple forms of breast cancer exist, a common theme in most of the forms involvesaberrations in signal transduction pathways that lead to inhibition of the programmed cell death process known as apoptosis. Apoptosis is a care ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Identification of potent and selective GLI1 inhibitors

    SBC: Zen-Bio, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Characterization of human tumor samples and cell lines in combination with inhibitor studies in animal models has established a central role for the Hh pathway in a vast array of cancer types, including small-cell lung, pancreatic, oesophageal, prostate, breast, colon, liver and ovarian cancers. Hh signaling is now implicated in approximately 20-25% of all can ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Targeted Polymer Micelles for Treatment of Metastatic Melanoma

    SBC: INTEZYNE TECHNOLOGIES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): According to the American Cancer Society, half of all men and one-third of all women in the United States will develop cancer in their lifetime. While chemotherapy has dramatically improved the survival rate of cancer patients, it comes at the cost of severe toxicities and in some cases poor response rates. In order to address these shortcomings, equal investme ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government